リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Direct Delivery of piggyBac CD19 CAR T Cells Has Potent Anti-tumor Activity against ALL Cells in CNS in a Xenograft Mouse Model」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Direct Delivery of piggyBac CD19 CAR T Cells Has Potent Anti-tumor Activity against ALL Cells in CNS in a Xenograft Mouse Model

Tanaka, Kuniaki 京都大学 DOI:10.14989/doctor.k22882

2021.01.25

概要

The anti-CD19 chimeric antigen receptor (CAR) T cells showed excellent effect against acute lymphoblastic leukemia (ALL) in bone marrow (BM) in clinical trials. However, it remains to be elucidated whether the CD19 CAR T cell therapy is effective for ALL cells in central nervous system (CNS) because the patients with isolated or advanced CNS disease were excluded from clinical trials of systemic intravenous (i.v.) delivery of CAR T cells. Therefore, the preclinical evaluation for the efficacy of CAR T cell therapy against ALL cells in CNS is essential for clinical application. We evaluated the effect and adverse reaction of CD19 CAR T cells against ALL in CNS using a xenograft mouse model by i.v. or intra-cerebroventricular (i.c.v.) delivery of CAR T cells. Injection of piggyBac CD19 CAR T cells by i.v. had partial effects, whereas all CAR T i.c.v.-delivered mice had eliminated ALL in CNS. Although some CAR T i.c.v.-delivered mice showed transient changes of clinical symptoms during the first few days after treatment, none of CAR T i.c.v.-delivered mice displayed fatal adverse events. In this study, we demonstrated that direct delivery into CNS of CAR T cells is a possible therapeutic approach with the xenograft mouse model.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M.R., Stefanski, H.E., Myers, G.D., et al. (2018). Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 378, 439–448.

2. Park, J.H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K.J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018). Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N. Engl. J. Med. 378, 449–459.

3. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25.

4. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., et al. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528.

5. Gardner, R.A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K.S., et al. (2017). Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322–3331.

6. Bollard, C.M., and Barrett, A.J. (2014). Cytotoxic T lymphocytes for leukemia and lymphoma. Hematology (Am. Soc. Hematol. Educ. Program) 2014, 565–569.

7. Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., and Begley, D.J. (2010). Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13–25.

8. Kato, I., Nishinaka, Y., Nakamura, M., Akarca, A.U., Niwa, A., Ozawa, H., Yoshida, K., Mori, M., Wang, D., Morita, M., et al. (2017). Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA. Blood 129, 3126–3129.

9. Priceman, S.J., Tilakawardane, D., Jeang, B., Aguilar, B., Murad, J.P., Park, A.K., Chang, W.C., Ostberg, J.R., Neman, J., Jandial, R., et al. (2018). Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. Clin. Cancer Res. 24, 95–105.

10. Nellan, A., Rota, C., Majzner, R., Lester-McCully, C.M., Griesinger, A.M., Mulcahy Levy, J.M., Foreman, N.K., Warren, K.E., and Lee, D.W. (2018). Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J. Immunother. Cancer 6, 30.

11. Yanagisawa, R., Nakazawa, Y., Sakashita, K., Saito, S., Tanaka, M., Shiohara, M., Shimodaira, S., and Koike, K. (2016). Intrathecal donor lymphocyte infusion for isolated leukemia relapse in the central nervous system following allogeneic stem cell transplantation: a case report and literature review. Int. J. Hematol. 103, 107–111.

12. Hirase, C., Maeda, Y., Takai, S., and Kanamaru, A. (2009). Hypersensitivity of Phpositive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. Leuk. Res. 33, 450–459.

13. Price, R.A., and Johnson, W.W. (1973). The central nervous system in childhood leukemia. I. The arachnoid. Cancer 31, 520–533.

14. Hagedorn, N., Acquaviva, C., Fronkova, E., von Stackelberg, A., Barth, A., zur Stadt, U., Schrauder, A., Trka, J., Gaspar, N., Seeger, K., et al.; Resistant Disease Committee of the International BFM study group (2007). Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of “isolated” and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood 110, 4022–4029.

15. Saito, S., Nakazawa, Y., Sueki, A., Matsuda, K., Tanaka, M., Yanagisawa, R., Maeda, Y., Sato, Y., Okabe, S., Inukai, T., et al. (2014). Anti-leukemic potency of piggyBacmediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy 16, 1257–1269.

16. Morita, D., Nishio, N., Saito, S., Tanaka, M., Kawashima, N., Okuno, Y., Suzuki, S., Matsuda, K., Maeda, Y., Wilson, M.H., et al. (2017). Enhanced Expression of AntiCD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol. Ther. Methods Clin. Dev. 8, 131–140.

17. Ghosh, A., Smith, M., James, S.E., Davila, M.L., Velardi, E., Argyropoulos, K.V., Gunset, G., Perna, F., Kreines, F.M., Levy, E.R., et al. (2017). Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versushost activity. Nat. Med. 23, 242–249.

18. Gust, J., Hay, K.A., Hanafi, L.A., Li, D., Myerson, D., Gonzalez-Cuyar, L.F., Yeung, C., Liles, W.C., Wurfel, M., Lopez, J.A., et al. (2017). Endothelial Activation and BloodBrain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 7, 1404–1419.

19. Santomasso, B.D., Park, J.H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018). Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 8, 958–971.

20. Mook-Kanamori, B., Geldhoff, M., Troost, D., van der Poll, T., and van de Beek, D. (2012). Characterization of a pneumococcal meningitis mouse model. BMC Infect. Dis. 12, 71.

21. Mount, C.W., Majzner, R.G., Sundaresh, S., Arnold, E.P., Kadapakkam, M., Haile, S., Labanieh, L., Hulleman, E., Woo, P.J., Rietberg, S.P., et al. (2018). Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat. Med. 24, 572–579.

22. Teachey, D.T., Lacey, S.F., Shaw, P.A., Melenhorst, J.J., Maude, S.L., Frey, N., Pequignot, E., Gonzalez, V.E., Chen, F., Finklestein, J., et al. (2016). Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 6, 664–679.

23. Hay, K.A., Hanafi, L.A., Li, D., Gust, J., Liles, W.C., Wurfel, M.M., López, J.A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017). Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295–2306.

24. Nguyen, K., Devidas, M., Cheng, S.C., La, M., Raetz, E.A., Carroll, W.L., Winick, N.J., Hunger, S.P., Gaynon, P.S., and Loh, M.L.; Children’s Oncology Group (2008). Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia 22, 2142–2150.

25. Pui, C.H., Cheng, C., Leung, W., Rai, S.N., Rivera, G.K., Sandlund, J.T., Ribeiro, R.C., Relling, M.V., Kun, L.E., Evans, W.E., and Hudson, M.M. (2003). Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N. Engl. J. Med. 349, 640–649.

26. Hunger, S.P., Lu, X., Devidas, M., Camitta, B.M., Gaynon, P.S., Winick, N.J., Reaman, G.H., and Carroll, W.L. (2012). Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J. Clin. Oncol. 30, 1663–1669.

27. Aldoss, I., Al Malki, M.M., Stiller, T., Cao, T., Sanchez, J.F., Palmer, J., Forman, S.J., and Pullarkat, V. (2016). Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia. Biol. Blood Marrow Transplant. 22, 575–578.

28. Hamidieh, A.A., Monzavi, S.M., Kaboutari, M., Behfar, M., and Esfandbod, M. (2017). Outcome Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia Treated with Total Body Irradiation-Free Allogeneic Hematopoietic Stem Cell Transplantation: Comparison of Patients with and Without Central Nervous System Involvement. Biol. Blood Marrow Transplant. 23, 2110–2117.

29. Laningham, F.H., Kun, L.E., Reddick, W.E., Ogg, R.J., Morris, E.B., and Pui, C.H. (2007). Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology 49, 873–888.

30. Krull, K.R., Brinkman, T.M., Li, C., Armstrong, G.T., Ness, K.K., Srivastava, D.K., Gurney, J.G., Kimberg, C., Krasin, M.J., Pui, C.H., et al. (2013). Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J. Clin. Oncol. 31, 4407–4415.

31. Mamonkin, M., Rouce, R.H., Tashiro, H., and Brenner, M.K. (2015). A T-celldirected chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126, 983–992.

32. Brown, C.E., Alizadeh, D., Starr, R., Weng, L., Wagner, J.R., Naranjo, A., Ostberg, J.R., Blanchard, M.S., Kilpatrick, J., Simpson, J., et al. (2016). Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N. Engl. J. Med. 375, 2561–2569.

33. Ahmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Kalra, M., Landi, D., Robertson, C., Gray, T.L., Diouf, O., Wakefield, A., et al. (2017). HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 3, 1094–1101.

34. Kasahara, K., Fukunaga, Y., Igura, S., Andoh, R., Saito, T., Suzuki, I., Kanemitsu, H., Suzuki, D., Goto, K., Nakamura, D., et al. (2017). Background data on NOD/Shi-scid IL-2Rgnull mice (NOG mice). J. Toxicol. Sci. 42, 689–705.

35. van Rijn, R.S., Simonetti, E.R., Hagenbeek, A., Hogenes, M.C., de Weger, R.A., Canninga-van Dijk, M.R., Weijer, K., Spits, H., Storm, G., van Bloois, L., et al. (2003). A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 102, 2522–2531.

36. Smith, J.S., Angel, T.E., Chavkin, C., Orton, D.J., Moore, R.J., and Smith, R.D. (2014). Characterization of individual mouse cerebrospinal fluid proteomes. Proteomics 14, 1102–1106.

37. Kato, I., Niwa, A., Heike, T., Fujino, H., Saito, M.K., Umeda, K., Hiramatsu, H., Ito, M., Morita, M., Nishinaka, Y., et al. (2011). Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis. PLoS ONE 6, e27042.

38. Jena, B., Maiti, S., Huls, H., Singh, H., Lee, D.A., Champlin, R.E., and Cooper, L.J. (2013). Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS ONE 8, e57838.

39. Li, S., Zhang, J., Wang, M., Fu, G., Li, Y., Pei, L., Xiong, Z., Qin, D., Zhang, R., Tian, X., et al. (2018). Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB. Br. J. Haematol. 181, 360–371.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る